ERBB2 and breast cancer: Dr J Korkola from Oregon Health & Science University, Portland, OR and colleagues discussed the effect of sequential compared to concurrent treatment of pertuzumab plus T-DM1 (monoclonal antibody therapy) in HER-2+ breast cancer cell lines as a preclinical model system.